- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...

Tsukuba, Japan—Recombinant protein production for pharmaceuticals and other applications often involves infecting plants with bacteria carrying specific genes to accumulate desired proteins in plants.

Designing a high-density fed-batch, E. coli-based strategy to produce recombinant GLP-1 cuts upstream production costs 20–30%.

The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...

Focusing on the establishment of Sino Biological‘s Center for Bioprocessing (C4B) in Houston, it highlights how the ...

Microbial systems offer distinct advantages in protein expression, saving costs and time, and offering well-characterized host genetics and ease of scale-up. 2 However, challenges remain in process ...

PRESS RELEASE Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technologyAgreement includes R&D funding for exploratory work, technology access and, assuming exercise of ...

Stay up to date on the latest science with Brush Up Summaries. Finally, although transgenic animals and mammalian cell culture systems promote optimal expression due to correct protein modifications, ...